What is the risk of erectile dysfunction after transurethral resection of the prostate (TURP) and how should it be managed?

TURP and Erectile Dysfunction: Risk and Management

TURP does not significantly increase the risk of erectile dysfunction in most patients, and men with pre-existing ED often experience improvement after the procedure. 1, 2

Risk of ED After TURP

The evidence consistently demonstrates that TURP has minimal negative impact on erectile function:

• Patients with normal baseline erectile function maintain their function after TURP, with no significant changes in IIEF-5 scores at 6-month follow-up (22.88 ± 0.81 vs 22.63 ± 2.63, p = 0.065) 1

• Patients with pre-existing ED actually show significant improvement in erectile function after TURP, with sustained improvements at 1,3, and 6 months post-operatively (p < 0.001) 1, 2

• The incidence of newly reported ED after TURP ranges from 12-23% in various studies, but this must be interpreted carefully as age is a major confounding factor 3, 4

Key Risk Factors for Post-TURP ED

When new ED does occur after TURP, specific risk factors have been identified:

• Age is the single most important independent risk factor - patients over 65 years have significantly higher risk of developing ED after TURP (p < 0.0001) 3

• Diabetes mellitus (p = 0.003, relative risk = 3.67) 4

• Intraoperative capsular perforation (p = 0.02, relative risk = 1.12) 4

• Operating time, catheterization duration, BMI, hypertension, and dyslipidemia do not significantly affect post-TURP erectile function 3

Important Caveat: Ejaculatory Dysfunction

While erectile function is preserved or improved, ejaculatory dysfunction (retrograde ejaculation) occurs in approximately 50-57% of patients after TURP and is comparable across different surgical techniques 5, 1. This is a critical counseling point that must be distinguished from erectile dysfunction.

Management Approach

For patients who develop ED after TURP, management follows standard ED treatment algorithms 6, 7:

1. First-line therapy: PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) - these remain the gold standard oral therapy 6, 8

2. Second-line options for PDE5i failures or contraindications:

   • Intraurethral alprostadil (64.9% success rate for achieving intercourse) 6
   • Intracavernosal injection therapy (alprostadil or combination therapy) - requires in-office test dose and proper training 6

3. Third-line therapy: Penile prosthesis implantation - for refractory cases, with infection rates of 1-2% when using coated devices 6

Clinical Pitfalls to Avoid

• Do not attribute all post-TURP sexual dysfunction to the surgery itself - age-related decline and pre-existing vascular disease are often the primary culprits 3

• Distinguish between erectile and ejaculatory dysfunction during patient counseling - patients often conflate these two distinct issues 1

• Screen for diabetes and optimize glycemic control before and after TURP, as this is a modifiable risk factor 4

• Counsel patients preoperatively that those with existing ED may actually see improvement, while ejaculatory changes are expected 1, 2